Data were generated using ring-stage and trophozoite-stage survival assays, prepared with synchronized parasites beginning 0-3 hr and 18-21 hr post-invasion (the RSA 0-3h and TSA 18-21h ) respectively. Parasites were exposed to 700 nM dihydroartemisinin for 6 hr, the drug removed by washing, and survival measured after 66 hr of further culture. The parasitemia of surviving parasites was determined by flow cytometry of 20,000-35,000 parasites stained with SYBR Green I and Mitotracker Deep Red. Assays were performed in duplicate on three separate occasions. Survival values (calculated for each line and assay as a percent survival of DMSO-control treated parasites from that same line) are shown as means ± SEM. Mann-Whitney U tests showed no significant difference between pfmdr1-modified lines and the parental NF10 control. As a positive control for the RSA 0-3h , we included the Cam3.II R539T line, which expresses the K13 R539T mutation that confers in vitro ring-stage resistance to dihydroartemisinin. 
Supplementary Figure 4 | Allelic exchange strategy employed to introduce F1226Y into
PfMDR1. (A) pmdr1 SNYD contains the last 2.1 kb of pfmdr1 coding sequence, followed by a 0.7 kb fragment of the P. yoelii mdr1 3' UTR, and a blasticidin selectable marker (bsd). The pfmdr1 sequence within the plasmid was modified by site-directed mutagenesis of the pmdr1 SNFD plasmid 24 using primers p15 and p16 to introduce the mutation encoding 1226Y.
The endogenous K1 pfmdr1 locus is flanked by P. falciparum 3' and 5' UTR elements and carries the wild-type F1226 allele. K1 parasites were transfected with pmdr1 SNYD to introduce the F1226Y mutation or with pmdr1 SNFD to obtain a recombinant control with an unchanged pfmdr1 allele. Transfected parasites were selected with 1.25-2.0 µg/ml blasticidin. Supplementary Table 2 | Copy number analysis of pfmdr1-modified recombinant lines.
pfmdr1 copy number was determined using a published Taqman assay (see Methods). n.d., not determined.
0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0. 
